Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...

The phase and the group velocity of light propagating in conventional optical media cannot exceed the speed of light in ...

The new demand charge will apply to the two lowest levels of energy use, the G1 and G2 customers. These are mostly residences and make up 92% of OCEC’s meters. Larger G3 and G4 customers already pay a ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

Navy Yard is one of the busiest development neighborhoods in DC, with nearly 3,500 residential units in the pipeline. Below, ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Here’s everything you need to know about Samsung’s latest flagship phones. I’m one of PCMag’s mobile analysts. That means I check out phones, hotspots, and mobile networks. Technology has ...

it’s like it has worked magic to beef up my strands. Not only is my hair longer but it feels twice as thick. I’ve been through a handful of bottles of the shampoo and conditioner in particular — and I ...

We are thrilled to continue our strategic partnership with OpenAI and to partner on Stargate. Today’s announcement is complementary to what our two companies have been working on together since 2019.

Barcelos F, Martins C, Madeira N, Ângelo-Dias M, Cardigos J, Alves N, Vaz-Patto J, Cunha-Branco J, Borrego LM. Lymphocyte subpopulations in Sjögren's syndrome are distinct in anti-SSA-positive ...